Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

IDO1 (Indoleamine 2,3-dioxygenase 1)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

IDO1 expression	Melanoma	IDO1 expression	Melanoma	nivolumab Sensitive: C2 – Inclusion Criteria nivolumab Sensitive : C2	nivolumab Sensitive: C2 – Inclusion Criteria nivolumab Sensitive : C2
IDO1 expression	Melanoma	IDO1 expression	Melanoma	pembrolizumab Sensitive: C2 – Inclusion Criteria pembrolizumab Sensitive : C2	pembrolizumab Sensitive: C2 – Inclusion Criteria pembrolizumab Sensitive : C2
IDO1 expression	Melanoma	IDO1 expression	Melanoma	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
IDO1 overexpression	Melanoma	IDO1 overexpression	Melanoma	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
IDO1 overexpression	Squamous Cell Carcinoma of Head and Neck	IDO1 overexpression	Squamous Cell Carcinoma of Head and Neck	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
IDO1 positive	Melanoma	IDO1 positive	Melanoma	pembrolizumab + INCB024360 Sensitive: C3 – Early Trials pembrolizumab + INCB024360 Sensitive : C3	pembrolizumab + INCB024360 Sensitive: C3 – Early Trials pembrolizumab + INCB024360 Sensitive : C3
IDO1 expression	Non Small Cell Lung Cancer	IDO1 expression	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
IDO1 overexpression	Non Small Cell Lung Cancer	IDO1 overexpression	Non Small Cell Lung Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3